MedImmune Emerges As Potential Takeover Target With Vaccines, Synagis
Executive Summary
MedImmune's growing vaccine franchise and recently revised co-marketing arrangement for Synagis (palivizumab) may position the firm well for a takeover
You may also be interested in...
Investors Judge Biotech Harshly: PDL BioPharma, MedImmune, Amgen Disappoint
Biotechnology investors could experience palpitations after this past quarter's dismal performance on the "The Pink Sheet" Index of NASDAQ stocks
Investors Judge Biotech Harshly: PDL BioPharma, MedImmune, Amgen Disappoint
Biotechnology investors could experience palpitations after this past quarter's dismal performance on the "The Pink Sheet" Index of NASDAQ stocks
GSK Vaccine Portfolio Gets A Shot In The Arm From ID Biomedical Buy
GlaxoSmithKline's proposed acquisition of ID Biomedical, announced Sept. 7, will bolster the drug maker's growing vaccine portfolio with the addition of Fluviral and several pipeline products